ClinicalTrials.gg
CompletedNCT01057589Updated Sep 18, 2013Results posted

A Study for Patients With Recurrent or Metastatic Squamous Cell Head and Neck Cancer

A Phase 2 interventional study of Pemetrexed and Cetuximab in Head and Neck Neoplasms, sponsored by Eli Lilly and Company. Completed at 13 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-09-18.

Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
66
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies testing pemetrexed in Head and Neck Neoplasms — 1 open to participants now, 1 under way, none of them phase 3. Pemetrexed · Head and Neck Neoplasms.

Enrollment
4th of 13
66 · median 36
Started
2010
with 1 other
Phase 2
8 of 13
1 open now
Registered
8th of 13
by date
Lead sponsor
3 of 13
Eli Lilly and Company

Among the 13 studies testing pemetrexed in Head and Neck Neoplasms, this one is the 4th largest by enrollment, is one of 2 that started in 2010, is one of 8 in phase 2, and was the 8th registered.

Head and Neck Neoplasms

2,714 studies on the registry are indexed under Head and Neck Neoplasms; 597 are open to participants now.

Browse Head and Neck Neoplasms studies →

Open to participants now

1 of the 13 studies testing pemetrexed in Head and Neck Neoplasms is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About pemetrexed

Pemetrexed: first FDA approval 2004 (ALIMTA), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 456 Head and Neck Neoplasms studies recruiting now, 348 (76%) set no upper age limit and 51 (11%) stop at 75 or younger; 22 take children under 18; 27 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies testing pemetrexed in Head and Neck Neoplasms, or all of them as a file.
02

Study summary

The purpose of this trial is to estimate progression free survival in patients with recurrent or metastatic head and neck cancer that have not received chemotherapy in this setting.

Read the detailed description

A 12 patient safety lead will evaluate side effects in patients receiving at least 2 cycles of the combination pemetrexed, cisplatin and cetuximab.

03

Conditions studied

  • Head and Neck Neoplasms

Keywords

  • Pharynx
  • Larynx
  • Cervical esophagus
  • Nose
  • Thyroid Gland
  • Parathyroid Gland
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed diagnosis of squamous cell carcinoma of head and neck (SCCHN)
  • Recurrent or SCCHN, not amenable to local therapy
  • At least 6 months since completion of systemic therapy (chemotherapy or biological anticancer therapy)
  • No more than 1 prior systemic therapy, given as part of multimodal treatment for locally advanced disease;
  • No prior systemic therapy for metastatic disease
  • Radiation therapy must be completed at least 4 weeks before study enrollment.
  • For palliative therapy, prior radiation therapy allowed to \<25% of the bone marrow (Cristy and Eckerman 1987), and prior radiation to the whole pelvis is not allowed.
  • Surgery (excluding prior diagnostic ) must be completed at least 4 weeks before study enrollment.
  • An estimated of at least 12 weeks.
  • (ECOG) performance status 0 or 1 (Oken et al. 1982).
  • Biological tissue available for biomarker analysis on tumor tissue.
  • Disease status may be measurable or nonmeasurable as defined by
  • Patient compliance and geographic proximity that allow for adequate follow-up.
  • Adequate organ function
  • Willingness to comply with Regimen
  • For women: Must be surgically sterile, , or compliant with a medically approved contraceptive regimen [for example, intrauterine device (IUD), birth control pills, or barrier device] during and for 6 months after the treatment period; must have a negative serum or urine pregnancy test within 7 days before study enrollment, and must not be breast-feeding. For men: Must be surgically sterile or compliant with a contraceptive regimen during and for 6 months after the treatment period.

Exclusion criteria

Exclusion Criteria:

  • Nasopharyngeal, paranasal sinus, lip, or salivary gland cancer.
  • Previously received treatment with monoclonal antibody therapy, or other signal transduction inhibitors of Epidermal Growth Factor Receptor therapy.
  • Are receiving concurrent chronic systemic immune therapy, or chemotherapy for a disease other than cancer.
  • Serious concomitant systemic disorder (for example, active infection) or psychiatric disorder that, in the opinion of the investigator, would compromise the patient's ability to complete the study.
  • Have serious cardiac disease, such as symptomatic , unstable angina, or the history of myocardial infarction in the previous 12 months.
  • Second primary that is clinically detectable at the time of consideration for study enrollment.
  • Have had another primary malignancy other than Head and Neck cancer, unless that prior malignancy was treated at least 2 years previously with no evidence of recurrence. Exception: Patients with a history of in situ carcinoma of the cervix, nonmelanoma skin cancer, or low-grade (Gleason score less than or equal to 6) localized prostate cancer will be eligible even if diagnosed and treated less than 2 years previously.
  • Presence of (by physical exam) third-space fluid collections; for example, ascites or pleural effusions that cannot be controlled by drainage or other procedures prior to study entry.
  • Have peripheral neuropathy
  • Have central nervous system (CNS) (unless the patient has completed successful local therapy for and has been off for at least 4 weeks before starting study therapy). Brain imaging is required in symptomatic patients to rule out brain metastases, but is not required in asymptomatic patients.
  • Inability to interrupt aspirin or other nonsteroidal anti-inflammatory agents, other than an aspirin dose less than or equal to 1.3 grams per day, for a 5-day period (8-day period for long-acting agents, such as piroxicam).
  • Unable or unwilling to take folic acid, vitamin B12, or prophylactic corticosteroids.
  • Recent (within 30 days before enrollment) or concurrent yellow fever vaccination.
  • Pregnant or breast-feeding
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
66 participants (actual)

Study arms

  • Experimental
    Pemetrexed + Cisplatin + Cetuximab

    Participants will receive pemetrexed,cisplatin and cetuximab for up to 6 cycles (21 days per cycle) followed by optional maintenance of pemetrexed and cetuximab until disease progression. Optional maintenance therapy is permitted after at least 4 cycles of triplet combination therapy have been given. Cetuximab will be administered as an initial dose of 400 milligram per meter squared (mg/m\^2) intravenous (IV) infusion and as a 250 mg/m\^2 IV weekly dose thereafter. As Standard of care dietary supplements included: 350 to 1000 micrograms (µg) oral Folic Acid 5 times a day for the 7 days preceding the first dose of first dose of pemetrexed and continuing throughout treatment and for 21 days after the last dose of pemetrexed and 1000 µg vitamin B12 intramuscular injection (IM) during the week preceding the first dose of pemetrexed and every 9 weeks thereafter.

    Drug: Pemetrexed · Drug: Cetuximab · Drug: Cisplatin · Dietary Supplement: Folic Acid · Dietary Supplement: Vitamin B12

Interventions

  • Triplet Combination Therapy: 500 mg/m\^2 administered intravenously on Day 1 of 21 day cycle for up to 6 cycles Maintenance Therapy: 500mg/m\^2 administered intravenously on Day 1 of 21 day cycle until disease progression or unacceptable toxicity

    Also known as: Alimta, LY231514

  • Triplet Combination Therapy: 400 mg/m\^2 administered intravenously on Day 1 of 21 day cycle for 1 cycle; 250 mg/m\^2 administered IV infusion on Day 1 of 21 day cycle and then weekly for up to 6 cycles. Maintenance Therapy: 250 mg/m\^2 administered intravenously on Day 1 of 21 day cycle and then weekly until disease progression or unacceptable toxicity

  • Triplet Combination Therapy: 75mg/m\^2 administered intravenously on Day 1 of 21 day cycle for up to 6 cycles.

  • Dietary supplementFolic Acid

    Standard of care dietary supplements: 350 to 1000 µg orally 5 times a day for the 7 days preceding the first dose of first dose of pemetrexed and continuing throughout treatment and for 21 days after the last dose of pemetrexed.

  • Dietary supplementVitamin B12

    Standard of care dietary supplements: 1000 µg IM during the week preceding the first dose of pemetrexed and every 9 weeks thereafter.

06

What researchers measure

Primary outcomes

  1. Progression Free Survival (PFS)

    PFS based on Response Evaluation Criteria in Solid Tumors (RECIST) Guidelines defined as the time from the date of first dose of study drug to first documented objective progressive disease (PD) or death from any cause. PD is defined as at least a 20% increase in the sum of longest diameter (LD) of target lesions taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions.

    Time frame: Baseline to date of PD or death up to 18.7 months

Secondary outcomes

  1. Overall Survival (OS)

    OS defined as the time from the date of first dose of study drug to the date to death from any cause.

    Time frame: Baseline to date of death up to 18.7 months

  2. Percent of Participants With a Partial Response (PR) or a Complete Response (CR)

    CR and PR based on RECIST Guidelines: CR is defined as the disappearance of all tumor lesions; PR is defined as at least a 30% decrease in the sum of the LD of target lesions taking as reference the baseline sum LDs or the complete disappearance of target lesions, with persistence (but not worsening) of one or more nontarget lesions and the appearance of no new lesions. PD is defined as at least a 20% increase in the sum of LD of target lesions taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions.

    Time frame: Date of first response to PD (up to 18.7 months)

  3. Change From Baseline in Participant Reported European-Quality of Life 5 Dimension Instrument (EQ-5D) Visual Analog Scale (VAS) at End of Triplet Combination Therapy and End of Maintenance Therapy

    Vertical VAS - a 20 millimeter (mm), fractionated scale in the form of a thermometer with endpoints of 0 (worst imaginable health state) and 100 (best imaginable health state). Participants used the EQ-5D VAS scale to rate their overall health on the day the questionnaire was administered. Possible change values range from -100 (best imaginable health at baseline changed to worst possible health at visit) to 100 (worst possible health at baseline changed to best possible health at visit).

    Time frame: Baseline, End of Triplet Combination Therapy (up to Cycle 6 [4.2 months]), End of Maintenance Therapy (up to 18.7 months)

  4. Change From Baseline in Participant Reported EQ-5D Utility Score at End of Triplet Combination Therapy and End of Maintenance Therapy

    EQ-5D Index is derived by converting the Descriptive System (participant is required to rate health by checking 1 \[no limitation\], 2 \[some limitation\] or 3 \[severe or complete limitation\] in 5 dimensions \[mobility, self-care, usual activities, pain/comfort and anxiety/depression\]) to a single summary index. A utility value assigned to each individual's health state based on the absence or presence of moderate or severe problems in the 5 dimensions. A regression equation defines a utility value for these health states. The possible values for health utility ranged from -0.59 (severe problems in all 5 dimensions) to 1 (no problem in all dimensions) on a scale where 0 represents death and 1 represents the best possible health state. Possible change values range from -1.59 (no problems at baseline to severe problems at visit) to 1.59 (severe problems at baseline to no problems at visit).

    Time frame: Baseline, End of Triplet Combination Therapy (up to 6 cycles [4.2 months]) , End of Maintenance Therapy (up to 18.7 months)

  5. Change From Baseline in Performance Status Scale for Head and Neck Cancer Patients (PSS-HNC)

    PSS-HNC is a clinician-rated instrument designed to measure speaking and eating disabilities of participants with head and neck cancer and consists of 3 subscales: Normalcy of Diet (NOD) subscale measures the ability of the participants to eat a normal diet, scale ranged from 0 (non-oral feeding) to 100 (unrestricted diet); Understandability of Speech (UOS)subscale measured the degree a clinician was able to understand the participant's speech, subscale ranged from 0 (never understandable) to 100 (always understandable); Eating in Public (EIP) subscale, rating based on clinician question to the participant to report who he/she eats with and in what setting, subscale ranged from 0 (always eats alone) to 100 (no restriction of place, food, or companion). Change from baseline: negative value represents a decrease in function and a positive value represents an increase in function.

    Time frame: Baseline, Triplet Combination Therapy Cycles 2, 4, 6 (cycle = 21 days) and optional Maintenance Therapy Cycles 1, 3, 5 and 7 (cycle = 21 days)

07

Results

Posted Mar 19, 2013

Participant flow

Participant flow — Overall Study
MilestonePemetrexed + Cisplatin + Cetuximab
Started66
Completed0
Not completed66
Withdrew: Disease progression35
Withdrew: Adverse event10
Withdrew: Physician decision8
Withdrew: Withdrawal by subject3
Withdrew: Sponsor decision1
Withdrew: Death8
Withdrew: Lost to follow-up1

Outcome measures

PrimaryProgression Free Survival (PFS)

PFS based on Response Evaluation Criteria in Solid Tumors (RECIST) Guidelines defined as the time from the date of first dose of study drug to first documented objective progressive disease (PD) or death from any cause. PD is defined as at least a 20% increase in the sum of longest diameter (LD) of target lesions taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions.

Time frame:
Baseline to date of PD or death up to 18.7 months
Reported as:
Median · months
Progression Free Survival (PFS)
monthsPemetrexed Cisplatin Cetuximab
Progression Free Survival (PFS)4.4 (3.6 to 5.4)
SecondaryOverall Survival (OS)

OS defined as the time from the date of first dose of study drug to the date to death from any cause.

Time frame:
Baseline to date of death up to 18.7 months
Reported as:
Median · months
Overall Survival (OS)
monthsPemetrexed Cisplatin Cetuximab
Overall Survival (OS)9.7 (6.5 to 13.1)
SecondaryPercent of Participants With a Partial Response (PR) or a Complete Response (CR)

CR and PR based on RECIST Guidelines: CR is defined as the disappearance of all tumor lesions; PR is defined as at least a 30% decrease in the sum of the LD of target lesions taking as reference the baseline sum LDs or the complete disappearance of target lesions, with persistence (but not worsening) of one or more nontarget lesions and the appearance of no new lesions. PD is defined as at least a 20% increase in the sum of LD of target lesions taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions.

Time frame:
Date of first response to PD (up to 18.7 months)
Reported as:
Number · percentage of participants
Percent of Participants With a Partial Response (PR) or a Complete Response (CR)
percentage of participantsPemetrexed Cisplatin Cetuximab
Percent of Participants With a Partial Response (PR) or a Complete Response (CR)29.3 (18.1 to 42.7)
SecondaryChange From Baseline in Participant Reported European-Quality of Life 5 Dimension Instrument (EQ-5D) Visual Analog Scale (VAS) at End of Triplet Combination Therapy and End of Maintenance Therapy

Vertical VAS - a 20 millimeter (mm), fractionated scale in the form of a thermometer with endpoints of 0 (worst imaginable health state) and 100 (best imaginable health state). Participants used the EQ-5D VAS scale to rate their overall health on the day the questionnaire was administered. Possible change values range from -100 (best imaginable health at baseline changed to worst possible health at visit) to 100 (worst possible health at baseline changed to best possible health at visit).

Time frame:
Baseline, End of Triplet Combination Therapy (up to Cycle 6 [4.2 months]), End of Maintenance Therapy (up to 18.7 months)
Reported as:
Mean · units on a scale
Change From Baseline in Participant Reported European-Quality of Life 5 Dimension Instrument (EQ-5D) Visual Analog Scale (VAS) at End of Triplet Combination Therapy and End of Maintenance Therapy
units on a scalePemetrexed Cisplatin Cetuximab
Change at End of Triplet Therapy (n=23)-1.2 ± 14.28
Change at End of Maintenance Therapy (n=11)-10.6 ± 21.51
Statistical analysis
  • Pemetrexed Cisplatin Cetuximab · t-test, 2 sided · p = 0.697 (P-value is for Change at End of Triplet Combination Therapy. Threshold for statistical significance was 0.05.)
  • Pemetrexed Cisplatin Cetuximab · t-test, 2 sided · p = 0.132 (P-value is for Change at End of Maintenance Therapy. Threshold for statistical significance was 0.05.)
SecondaryChange From Baseline in Participant Reported EQ-5D Utility Score at End of Triplet Combination Therapy and End of Maintenance Therapy

EQ-5D Index is derived by converting the Descriptive System (participant is required to rate health by checking 1 \[no limitation\], 2 \[some limitation\] or 3 \[severe or complete limitation\] in 5 dimensions \[mobility, self-care, usual activities, pain/comfort and anxiety/depression\]) to a single summary index. A utility value assigned to each individual's health state based on the absence or presence of moderate or severe problems in the 5 dimensions. A regression equation defines a utility value for these health states. The possible values for health utility ranged from -0.59 (severe problems in all 5 dimensions) to 1 (no problem in all dimensions) on a scale where 0 represents death and 1 represents the best possible health state. Possible change values range from -1.59 (no problems at baseline to severe problems at visit) to 1.59 (severe problems at baseline to no problems at visit).

Time frame:
Baseline, End of Triplet Combination Therapy (up to 6 cycles [4.2 months]) , End of Maintenance Therapy (up to 18.7 months)
Reported as:
Mean · units on a scale
Change From Baseline in Participant Reported EQ-5D Utility Score at End of Triplet Combination Therapy and End of Maintenance Therapy
units on a scalePemetrexed Cisplatin Cetuximab
Change at End of Triplet Therapy (n=29)0.05 ± 0.230
Change at End of Maintenance Therapy (n=15)-0.02 ± 0.291
Statistical analysis
  • Pemetrexed Cisplatin Cetuximab · t-test, 2 sided · p = 0.223 (P-value is for Change at End of Triplet Combination Therapy. Threshold for statistical significance was 0.05.)
  • Pemetrexed Cisplatin Cetuximab · t-test, 2 sided · p = 0.788 (P-value is for Change at End of Maintenance Therapy. Threshold for statistical significance was 0.05.)
SecondaryChange From Baseline in Performance Status Scale for Head and Neck Cancer Patients (PSS-HNC)

PSS-HNC is a clinician-rated instrument designed to measure speaking and eating disabilities of participants with head and neck cancer and consists of 3 subscales: Normalcy of Diet (NOD) subscale measures the ability of the participants to eat a normal diet, scale ranged from 0 (non-oral feeding) to 100 (unrestricted diet); Understandability of Speech (UOS)subscale measured the degree a clinician was able to understand the participant's speech, subscale ranged from 0 (never understandable) to 100 (always understandable); Eating in Public (EIP) subscale, rating based on clinician question to the participant to report who he/she eats with and in what setting, subscale ranged from 0 (always eats alone) to 100 (no restriction of place, food, or companion). Change from baseline: negative value represents a decrease in function and a positive value represents an increase in function.

Time frame:
Baseline, Triplet Combination Therapy Cycles 2, 4, 6 (cycle = 21 days) and optional Maintenance Therapy Cycles 1, 3, 5 and 7 (cycle = 21 days)
Reported as:
Mean · units on a scale
Change From Baseline in Performance Status Scale for Head and Neck Cancer Patients (PSS-HNC)
units on a scalePemetrexed Cisplatin Cetuximab
NOD-Change at Triplet Cycle 2 (n=53)-0.4 ± 20.8
NOD-Change at Triplet Cycle 4 (n=41)3.9 ± 24.2
NOD-Change at Triplet Cycle 6 (n=24)3.3 ± 23.5
NOD-Change at Maintenance Cycle 1 (n=23)0.4 ± 29.9
NOD-Change at Maintenance Cycle 3 (n=10)-1.0 ± 21.3
NOD-Change at Maintenance Cycle 5 (n=6)8.3 ± 20.4
NOD-Change at Maintenance Cycle 7 (n=5)-8.0 ± 11.0
EIP-Change at Triplet Cycle 2 (n=46)2.7 ± 25.4
EIP-Change at Triplet Cycle 4 (n=37)-6.8 ± 29.3
EIP-Change at Triplet Cycle 6 (n=22)-3.4 ± 20.8
EIP-Change at Maintenance Cycle 1 (n=23)-8.7 ± 38.1
EIP-Change at Maintenance Cycle 3 (n=10)-10.0 ± 21.1
EIP-Change at Maintenance Cycle 5 (n=6)-4.2 ± 24.6
EIP-Change at Maintenance Cycle 7 (n=5)-15.0 ± 22.4
UOS-Change at Triplet Cycle 2 (n=53)0.5 ± 18.0
UOS-Change at Triplet Cycle 4 (n=41)-4.3 ± 17.6
UOS-Change at Triplet Cycle 6 (n=24)-10.4 ± 22.0
UOS-Change at Maintenance Cycle 1 (n=23)-1.1 ± 14.1
UOS-Change at Maintenance Cycle 3 (n=10)-2.5 ± 7.9
UOS-Change at Maintenance Cycle 5 (n=6)-12.5 ± 34.5
UOS-Change at Maintenance Cycle 7 (n=5)-15.0 ± 33.5
Statistical analysis
  • Pemetrexed Cisplatin Cetuximab · t-test, 2 sided · p = 0.90 (P-value is for NOD, Triplicate Combination Therapy Cycle 2. Threshold for statistical significance was 0.05.)
  • Pemetrexed Cisplatin Cetuximab · t-test, 2 sided · p = 0.31 (P-value is for NOD, Triplicate Combination Therapy Cycle 4. Threshold for statistical significance was 0.05.)
  • Pemetrexed Cisplatin Cetuximab · t-test, 2 sided · p = 0.49 (P-value is for NOD, Triplicate Combination Therapy Cycle 6. Threshold for statistical significance was 0.05.)
  • Pemetrexed Cisplatin Cetuximab · t-test, 2 sided · p = 0.95 (P-value is for NOD, Maintenance Cycle 1. Threshold for statistical significance was 0.05.)
  • Pemetrexed Cisplatin Cetuximab · t-test, 2 sided · p = 0.89 (P-value is for NOD, Maintenance Cycle 3. Threshold for statistical significance was 0.05.)
  • Pemetrexed Cisplatin Cetuximab · t-test, 2 sided · p = 0.36 (P-value is for NOD, Maintenance Cycle 5. Threshold for statistical significance was 0.05.)
  • Pemetrexed Cisplatin Cetuximab · t-test, 2 sided · p = 0.18 (P-value is for NOD, Maintenance Cycle 7. Threshold for statistical significance was 0.05.)
  • Pemetrexed Cisplatin Cetuximab · t-test, 2 sided · p = 0.47 (P-value is for EIP, Triplicate Combination Cycle 2. Threshold for statistical significance was 0.05.)
  • Pemetrexed Cisplatin Cetuximab · t-test, 2 sided · p = 0.17 (P-value is for EIP, Triplicate Combination Cycle 4. Threshold for statistical significance was 0.05.)
  • Pemetrexed Cisplatin Cetuximab · t-test, 2 sided · p = 0.45 (P-value is for EIP, Triplicate Combination Cycle 6. Threshold for statistical significance was 0.05.)
  • Pemetrexed Cisplatin Cetuximab · t-test, 2 sided · p = 0.29 (P-value is for EIP, Maintenance Cycle 1. Threshold for statistical significance was 0.05.)
  • Pemetrexed Cisplatin Cetuximab · t-test, 2 sided · p = 0.17 (P-value is for EIP, Maintenance Cycle 3. Threshold for statistical significance was 0.05.)
  • Pemetrexed Cisplatin Cetuximab · t-test, 2 sided · p = 0.70 (P-value is for EIP, Maintenance Cycle 5. Threshold for statistical significance was 0.05.)
  • Pemetrexed Cisplatin Cetuximab · t-test, 2 sided · p = 0.21 (P-value is for EIP, Maintenance Cycle 7. Threshold for statistical significance was 0.05.)
  • Pemetrexed Cisplatin Cetuximab · t-test, 2 sided · p = 0.85 (P-value is for UOS, Triplicate Combination Cycle 2. Threshold for statistical significance was 0.05.)
  • Pemetrexed Cisplatin Cetuximab · t-test, 2 sided · p = 0.13 (P-value is for UOS, Triplicate Combination Cycle 4. Threshold for statistical significance was 0.05.)
  • Pemetrexed Cisplatin Cetuximab · t-test, 2 sided · p = 0.03 (P-value is for UOS, Triplicate Combination Cycle 6. Threshold for statistical significance was 0.05.)
  • Pemetrexed Cisplatin Cetuximab · t-test, 2 sided · p = 0.71 (P-value is for UOS, Maintenance Cycle 1. Threshold for statistical significance was 0.05.)
  • Pemetrexed Cisplatin Cetuximab · t-test, 2 sided · p = 0.34 (P-value is for UOS, Maintenance Cycle 3. Threshold for statistical significance was 0.05)
  • Pemetrexed Cisplatin Cetuximab · t-test, 2 sided · p = 0.41 (P-value is for UOS, Maintenance Cycle 5. Threshold for statistical significance was 0.05)
  • Pemetrexed Cisplatin Cetuximab · t-test, 2 sided · p = 0.37 (P-value is for UOS, Maintenance Cycle 7. Threshold for statistical significance was 0.05)

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pemetrexed Cisplatin Cetuximab—45/66 (68.2%)65/66 (98.5%)
Most frequent serious events
Showing 10 of 68
Most frequent serious events
EventPemetrexed Cisplatin Cetuximab
PneumoniaInfections and infestations7/66
HypotensionVascular disorders5/66
AnaemiaBlood and lymphatic system disorders4/66
DiarrhoeaGastrointestinal disorders4/66
Febrile neutropeniaBlood and lymphatic system disorders3/66
LeukopeniaBlood and lymphatic system disorders3/66
NeutropeniaBlood and lymphatic system disorders3/66
PyrexiaGeneral disorders3/66
Respiratory tract infectionInfections and infestations3/66
Decreased appetiteMetabolism and nutrition disorders3/66
Most frequent other events
Showing 10 of 58
Most frequent other events
EventPemetrexed Cisplatin Cetuximab
FatigueGeneral disorders40/66
RashSkin and subcutaneous tissue disorders31/66
Decreased appetiteMetabolism and nutrition disorders29/66
NauseaGastrointestinal disorders27/66
AnaemiaBlood and lymphatic system disorders26/66
LeukopeniaBlood and lymphatic system disorders26/66
NeutropeniaBlood and lymphatic system disorders26/66
ConstipationGastrointestinal disorders25/66
VomitingGastrointestinal disorders22/66
Mucosal inflammationGeneral disorders22/66

Baseline characteristics

Age Continuous
Age Continuous(years)Pemetrexed Cisplatin Cetuximab
Mean61.8 ± 9.56
Sex: Female, Male
Sex: Female, Male(Participants)Pemetrexed Cisplatin Cetuximab
Female13
Male53
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Pemetrexed Cisplatin Cetuximab
White66
Region of Enrollment
Region of Enrollment(participants)Pemetrexed Cisplatin Cetuximab
Belgium8
France4
Germany32
Italy8
Spain13
United Kingdom1
08

Study locations

13 sites
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Edegem, 2650, Belgium
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Saint Herblain, 44805, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Dresden, 01307, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Essen, 45122, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Hannover, 30625, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Leipzig, 04103, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Milano, 20133, Italy
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Barcelona, 08041, Spain
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Madrid, 28041, Spain
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Pamplona, 31008, Spain
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Valencia, 46014, Spain
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Cardiff, South Glamorgan CF14 2TL, United Kingdom
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    London, SW3 6JJ, United Kingdom
09

References and documents

Publications

  • Cristy M, Eckerman KF. 1987. Specific absorbed fractions of energy at various ages from internal sources: I. methods. Prepared by the Oak Ridge National Laboratory, Oak Ridge, Tenn.
  • Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982 Dec;5(6):649-55. No abstract available. PubMed 7165009 ↗
  • Vermorken JB, Licitra L, Stohlmacher-Williams J, Dietz A, Lopez-Picazo JM, Hamid O, Hossain AM, Chang SC, Gauler TC. Phase II study of pemetrexed in combination with cisplatin and cetuximab in recurrent or metastatic squamous cell carcinoma of the head and neck. Eur J Cancer. 2013 Sep;49(13):2877-83. doi: 10.1016/j.ejca.2013.05.002. Epub 2013 May 30. PubMed 23726971 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2010, a primary completion of Feb 2012 and a completion of Oct 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2013, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 20, 2010
First posted
Jan 27, 2010
Start
Feb 2010
Primary completionActual
Feb 2012
CompletionActual
Oct 2012
Results first posted
Mar 19, 2013
Last update
Sep 18, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 18, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01057589
Responsible party
Sponsor
First posted
Jan 27, 2010
Start date
Feb 2010
Primary completion
Feb 2012
Completion
Oct 2012
Results posted
Mar 19, 2013
Last update
Sep 18, 2013

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5PM Eastern time (UTC/GMT - 5 hours, EST
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Pemetrexed · Cetuximab · Cisplatin

Start the discussion